Click Here to return To Results

 

Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke Stroke 49:2237-2240, Jin, C.,et al, 2018 See this aricle in Pubmed Article Abstract These preliminary observations suggest that tPA may be reasonably well tolerated without prohibitive risks of bleeding complications in selected patients on NOACs. Reversal of anticoagulant effects by idarucizumab for dabigatran-treated patients before tPA is an emerging strategy that was associated with more favorable outcomes.

Related Tags

(click to filter results - removes previous filter) anticoagulant,treatment anticoagulant,treatment in CVD apixaban cerebrovascular accident cerebrovascular accident,acute management of cerebrovascular accident,thrombolytic agents in treatment complications dabigatran factor Xa inhibitor fibrinolytic agents fibrinolytic agents,complications fibrinolytic therapy,selection criteria idarucizumab non-vitamin K antagonist oral anticoagulants rivaroxaban safety tissue plasminogen activator,intravenous treatment of neurologic disorder

Click Here to return To Results